Related Experiment Video

Updated: Aug 21, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

[Homocysteine as the factor of atherosclerosis risk]

Beata Jołda-Mydłowska1

  • 1Katedra i Klinika Kardiologii Akademii Medycznej we Wrocławiu.

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|November 3, 2004
PubMed

Insights

Elevated homocysteine levels (hyperhomocysteinemia) are a potential risk factor for cardiovascular diseases. Higher concentrations correlate with increased cardiovascular mortality, especially when combined with other risk factors.

Area of Science:

  • Cardiovascular Science
  • Metabolic Disorders
  • Epidemiology

Context:

  • Hyperhomocysteinemia, characterized by elevated homocysteine levels, is increasingly recognized as a significant factor in cardiovascular disease (CVD) development.
  • Scientific evidence suggests homocysteine contributes to thrombogenesis and atherosclerosis, exacerbating risks from factors like smoking and hypertension.

Purpose:

  • To review the scientific literature on the role of hyperhomocysteinemia as a risk factor for cardiovascular diseases.
  • To discuss the implications of elevated homocysteine concentrations on cardiovascular mortality and morbidity.

Summary:

  • Epidemiological and experimental data indicate hyperhomocysteinemia is a potential risk factor for CVD in both homocysteinuria patients and the general population.
  • Elevated homocysteine concentrations (above 15 micromol/l fasting, 38 micromol/l post-methionine) are associated with doubled cardiovascular mortality.
  • Normal high homocysteine concentration is considered 10-15 micromol/l. Screening is recommended for high-risk groups, including diabetics and those with family history of CVD.

Impact:

  • Identifies hyperhomocysteinemia as a modifiable risk factor for cardiovascular diseases.
  • Highlights the need for targeted screening in specific patient populations.
  • Suggests potential benefits for primary and secondary cardiovascular disease prevention through hyperhomocysteinemia management, though prospective research is needed.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...